Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodium-glucose cotransporter-2 (SGLT2) inhibitor showed profound reno-protective effe...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Korean Diabetes Association 2020-08-01
Ráidu:	Diabetes & Metabolism Journal
Fáttát:	diabetes mellitus, type 2 glomerular filtration rate sodium-glucose transporter 2 inhibitors
Liŋkkat:	http://e-dmj.org/upload/pdf/dmj-44-489.pdf
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!